Use of activated protein C (drotrecogin alfa) in a patient with sepsis and respiratory failure on ultra high frequency jet ventilation.
Drotreocogin alfa is a recombinant form of human activated protein C that has recently been found to reduce mortality significantly when used in patients with severe sepsis. Bleeding is reported to be the most common adverse effect associated with the use of this drug. Patients with sepsis on Ultra High Frequency Jet Ventilator may develop necrotizing tracheobronchitis and may be at an increased risk of bleeding when treated with drotreocogin alfa. We describe a patient with sepsis and respiratory failure on Ultra High Frequency Jet Ventilator, who was started on drotrecogin alfa, without the development of any significant bleeding.